Market Cap 900.64M
Revenue (ttm) 169.12M
Net Income (ttm) -48.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 83.49
Profit Margin -28.87%
Debt to Equity Ratio 0.00
Volume 501,038
Avg Vol 1,173,776
Day's Range N/A - N/A
Shares Out 96.74M
Stochastic %K 64%
Beta 1.45
Analysts Strong Sell
Price Target $17.89

Latest News on AVDL

Avadel Pharmaceuticals: Moving To A Speculative Buy

Feb 11, 2025, 6:08 PM EST - 4 months ago

Avadel Pharmaceuticals: Moving To A Speculative Buy


3 Oversold Biotech Names

Jan 13, 2025, 12:56 PM EST - 5 months ago

3 Oversold Biotech Names

FOLD JAZZ VKTX XBI


Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook

Jan 12, 2025, 3:26 AM EST - 5 months ago

Avadel Pharmaceuticals: Patient Attrition Weighs On 2025 Outlook


US FDA expands approval for Avadel's sleep disorder drug

Oct 17, 2024, 10:03 AM EDT - 8 months ago

US FDA expands approval for Avadel's sleep disorder drug


Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On

Sep 3, 2024, 8:30 AM EDT - 9 months ago

Avadel Pharmaceuticals: The Oxybate War With Jazz Waxes On


Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:27 PM EDT - 10 months ago

Avadel Pharmaceuticals plc (AVDL) Q2 2024 Earnings Call Transcript


Avadel Pharmaceuticals to Join Russell 3000® Index

Jun 27, 2024, 4:05 PM EDT - 1 year ago

Avadel Pharmaceuticals to Join Russell 3000® Index


Avadel Pharmaceuticals Issues Statement On Patent Litigation

Mar 4, 2024, 3:37 PM EST - 1 year ago

Avadel Pharmaceuticals Issues Statement On Patent Litigation


Avadel May Continue To Outperform With Positive Launch Momentum

Jan 11, 2024, 11:31 AM EST - 1 year ago

Avadel May Continue To Outperform With Positive Launch Momentum